Bardoxolone methyl - CAS 218600-53-4
Catalog number: B0084-427948
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Certificate of Analysis-Bardoxolone methyl 218600-53-4 B15L1212  
Bardoxolone methyl (also known as “RTA 402” and “CDDO-methyl ester”) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-427948 250 mg $198 In stock
Bulk Inquiry
≥ 98.0%
Off-white to yellow powder
Bardoxolone methyl; CDDO Methyl ester; CDDOMe; NSC 713200; RTA 402; RTA-402; RTA402; TP-155; TP155; TP 155; methyl (4aS,6aR,6bS,8aR,12aS,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate; 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid methyl ester; bardoxolone methyl; CDDO methyl ester; CDDO-Me; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate; (4aS,6aR,6bS,8aR,12aS,14bS)-Methyl 11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicene-4a-carboxylate; 218600-53-4; C32H43NO4; CTK8B4664; ANW-45842;
AKOS015998607; MP-2040; AK-59714; TX-017703; ST24020580; W4516; W-201897; Bardoxolone methyl
Soluble in DMSO, not in water
Store in dry, dark and ventilated place.
A Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells; Antioxidant inflammation modulator (AIM); For the treatment of advanced chronic kidney disease (CKD) in type 2 diabetes mellitus patients
Quality Standard:
In-house standard
Boiling Point:
600.8ºC at 760 mmHg
1.15 g/cm3
Canonical SMILES:
Current Developer:
Reata Pharmaceuticals Inc; Abbott Laboratories; Kyowa Hakko Kirin
1.Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease
Hyun Woo Kim · Chang-Keun Lee · Hoon-Suk Cha. Rheumatol Int (2015) 35:727–734
Therapies effective in slowing the decrease in kidney function mainly focus on the control of blood pressure, optimization of the renin–angiotensin–aldosterone system blockade, and glycemic control in diabetes mellitus. However, the current therapies cannot be regarded as best because they are only partially effective. Therefore, there have been a number of trials demonstrating the efficacy of novel therapeutic strategies for slowing or even preventing the progression of CKD, but large number of drugs failed to afford renoprotection. For example, treatment with bardoxolone methyl, an anti-oxidative and anti-inflammatory drug, which activates the nuclear factor-erythroid-2-related factor-Keap1 pathway, resulted in a significant increase and maintenance in eGFR in patients with type 2 diabetes and CKD stage 3 or 4. However, the BEACON trial, which was designed to assess whether bardoxolone methyl decreases the incidence of dialysis and can be safely used in patients with type 2 diabetes and CKD stage 4, showed that bardoxolone methyl did not reduce the risk of end-stage renal disease or death from cardiovascular causes and was early terminated because of excess mortality in the bardoxolone methyl treatment arm. On the other hand, growing evidence suggests that TNF-α plays a pathogenic role in CKD with a variety of etiologies, and pharmacological agents capable of suppressing this inflammatory mediator, such as mycophenolate mofetil and pentoxifylline have therapeutic potential.
2.Therapies on the Horizon for Diabetic Kidney Disease
Sadaf S. Khan & Susan E. Quaggin. Curr Diab Rep (2015) 15: 111
Bardoxolone methyl is a semisynthetic oleanane triterpenoid compound that possesses antioxidant properties through activation of nuclear factor erythroid derived 2 (Nrf-2) and inhibition of nuclear factor (NF)-kβ. Activation of NF-kβ promotes oxidative stress and is proinflammatory. The Nrf2 pathway is constitutively active and becomes upregulated in response to oxidative stress resulting in increased transcription of downstream gene targets. Synthetic triterpenoid bardoxolone methyl (CDDO-Methyl ester) is a potent inducer of the Nrf2/Keap1 pathway, which leads to Nrf2 translocation into the nucleus to upregulate antioxidant and cytoprotective genes. Bardoxolone methyl also has anti-inflammatory properties through its inhibition of the IKKβ/NF-kβ signaling pathway. Treatment with a bardoxolone methyl analog led to a reduction in glomerulosclerosis, interstitial fibrosis, and inflammation in rat models with CKD induced by 5/6 nephrectomy.
3.What Are New Avenues for Renal Protection, in Addition to RAAS Inhibition?
Shinji Hagiwara & Phillip Kantharidis & Mark E. Cooper. Curr Hypertens Rep (2012) 14:100–110
Bardoxolone methyl, an antioxidant inflammation modulator, activates the Keap1-Nrf2 pathway, which is involved in the downstream upregulation of multiple cytoprotective genes. In a phase 2, double-blind, randomized, placebo-controlled trial, 227 adults with CKD were assigned to receive placebo or bardoxolone methyl. Treatment with bardoxolone methyl for 52 weeks led to a sustained and significantly improved estimated glomerular filtration rate (GFR). The most frequent adverse events were muscle spasms, which were dose-related. Other adverse effects were hypomagnesemia, mild increases in alanine aminotransferase levels, and gastrointestinal effects. Bardoxolone methyl therefore appears to be an attractive therapeutic candidate in patients with CKD; larger, longerterm clinical studies are warranted to better assess its clinical utility.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related KEAP1-Nrf2 Products

CAS 1832713-02-6 RA 839

RA 839
(CAS: 1832713-02-6)

RA 839 is a selective inhibitor of the Keap1/Nrf2 interaction (Kd=6 uM) and a useful tool compound to study the biology of Nrf2. It binds noncovalently to the N...

CAS 932730-51-3 CDDO-EA

(CAS: 932730-51-3)

CDDO-EA is an activator of Nrf2/ARE. It has neuroprotective effect.

CAS 458-37-7 Curcumin

(CAS: 458-37-7)

Curcumin is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae).<br/>Nutritional supplement i...

CAS 1432500-66-7 ML 334

ML 334
(CAS: 1432500-66-7)

ML 334 is an inhibitor of Keap1-Nrf2 interaction. It can affect the cytoprotective responses to oxidative and electrophilic stress.

CAS 1362661-34-4 TAT 14

TAT 14
(CAS: 1362661-34-4)

TAT 14 is an Nrf2 activator and inhibits Nrf2/Keap1 interaction with neuroprotective activity. TAT 14 has been shown to induce upregulation of Nrf2 pathway down...

CAS 218600-44-3 Bardoxolone

(CAS: 218600-44-3)

Bardoxolone is a synthetic oleanane triterpenoid that exerts multifunctional activities in the control of cellular growth and differentiation. Bardoxolone is ca...

CAS 1474034-05-3 RTA-408

(CAS: 1474034-05-3)

RTA-408 is a member of the synthetic oleanane triterpenoid class of compounds and an activator of nuclear factor erythroid 2 [NF-E2]-related factor 2 (Nrf2, Nfe...

CAS 846557-71-9 ML 385

ML 385
(CAS: 846557-71-9)

ML 385 is a novel and specific inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2; IC50 = 1.9 µM). ML 385 blocks NRF2 transcriptional activity, and ...

Chemical Structure

CAS 218600-53-4 Bardoxolone methyl

Quick Inquiry

Verification code

Featured Items